New shot could soothe severe eczema in teens
NCT ID NCT07540442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MG-K10 in 180 teens aged 12-17 with moderate-to-severe eczema that hasn't responded well to creams. The drug is given as a shot every two weeks for a year. Researchers will check if it clears skin and reduces itching better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MG-K10 (a humanized monoclonal antibody injection)
- What this could lead to
- If it works, this could provide a new treatment option for teens with moderate-to-severe eczema, reducing skin inflammation and itching.
- What could go wrong
- This is a Phase 3 trial, but results are not yet available. The drug may not work better than placebo, and side effects are possible. It also requires ongoing injections, not a one-time cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital Of China Medical University
Shenyang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- New eczema drug enters first human tests
- Eczema drug study pulled before it started